{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:41:11Z","timestamp":1776400871174,"version":"3.51.2"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"19","license":[{"start":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T00:00:00Z","timestamp":1545868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI18C0070"],"award-info":[{"award-number":["HI18C0070"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2017R1A2B4003983"],"award-info":[{"award-number":["NRF-2017R1A2B4003983"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Although a recent expert consensus statement has recommended periprocedural uninterrupted (UI) non-vitamin K antagonist oral anticoagulants (NOACs) during catheter ablation of atrial fibrillation (AF) as a Class I indication, there have been no clear randomized trials. We investigated the safety and efficacy of UI, procedure day single-dose skipped (SDS), and 24-hour skipped (24S) NOACs in patients undergoing AF ablation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>In this prospective, open-label, randomized multicentre trial, 326 patients (75% male, 58\u2009\u00b1\u200911 years old) scheduled for AF catheter ablation were randomly assigned in a 1:1:1 ratio to UI, SDS, and 24S at three tertiary hospitals. Bridging with low molecular weight heparin was carried out in the patients with persistent AF who were assigned to the 24S group. Dabigatran, rivaroxaban, and apixaban were assigned in order after randomization. The primary endpoint was the incidence of bleeding events within 1 month after ablation. The secondary endpoints included thrombo-embolic and other procedure-related complications. The intra-procedural heparin requirement was higher in the 24S group than others (P\u2009&amp;lt;\u20090.001), and the mean activated clotting time was comparable among the groups (P\u2009=\u20090.139). The incidence of major bleeding up to 1 month after ablation and a post-procedural reduction in the haemoglobin levels did not significantly differ among the treatment groups and different NOACs (P\u2009&amp;gt;\u20090.05). There were no fatal events or thrombo-embolic complications in all the three groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In patients undergoing AF ablation, UI NOACs and SDS or double dose skipped NOACs had a comparable efficacy and safety, regardless of the type of NOAC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehy870","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T04:16:38Z","timestamp":1543551398000},"page":"1531-1537","source":"Crossref","is-referenced-by-count":37,"title":["When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study"],"prefix":"10.1093","volume":"40","author":[{"given":"Hee Tae","family":"Yu","sequence":"first","affiliation":[{"name":"Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaemin","family":"Shim","sequence":"additional","affiliation":[{"name":"Korea University Cardiovascular Center, 73 Inchon-ro, Seongbuk-gu, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junbeom","family":"Park","sequence":"additional","affiliation":[{"name":"Ewha Womans University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Hoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Sun","family":"Uhm","sequence":"additional","affiliation":[{"name":"Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Youn","family":"Kim","sequence":"additional","affiliation":[{"name":"Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyoung","family":"Joung","sequence":"additional","affiliation":[{"name":"Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon-Hyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Korea University Cardiovascular Center, 73 Inchon-ro, Seongbuk-gu, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Nam","family":"Pak","sequence":"additional","affiliation":[{"name":"Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,12,27]]},"reference":[{"key":"2022102605494906900_ehy870-B1","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1056\/NEJMoa1113566","article-title":"Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation","volume":"367","author":"Cosedis Nielsen","year":"2012","journal-title":"N Engl J Med"},{"key":"2022102605494906900_ehy870-B2","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1408288","article-title":"Approaches to catheter ablation for persistent atrial fibrillation","volume":"372","author":"Verma","year":"2015","journal-title":"N Engl J Med"},{"key":"2022102605494906900_ehy870-B3","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102605494906900_ehy870-B4","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"14","author":"Calkins","year":"2017","journal-title":"Heart Rhythm"},{"key":"2022102605494906900_ehy870-B5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1540-8167.2009.01670.x","article-title":"Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation","volume":"21","author":"Kwak","year":"2009","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2022102605494906900_ehy870-B6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10840-013-9813-7","article-title":"Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies","volume":"37","author":"Steinberg","year":"2013","journal-title":"J Interv Card Electrophysiol"},{"key":"2022102605494906900_ehy870-B7","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/eurheartj\/eht134","article-title":"EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"34","author":"Heidbuchel","year":"2013","journal-title":"Eur Heart J"},{"key":"2022102605494906900_ehy870-B8","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"2022102605494906900_ehy870-B9","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur Heart J"},{"key":"2022102605494906900_ehy870-B10","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","article-title":"Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation","volume":"376","author":"Calkins","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102605494906900_ehy870-B11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijcard.2014.11.182","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal","volume":"180","author":"Lip","year":"2015","journal-title":"Int J Cardiol"},{"key":"2022102605494906900_ehy870-B12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3349\/ymj.2016.57.2.342","article-title":"Early experience of novel oral anticoagulants in catheter ablation for atrial fibrillation: efficacy and safety comparison to warfarin","volume":"57","author":"Shin","year":"2016","journal-title":"Yonsei Med J"},{"key":"2022102605494906900_ehy870-B13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2022102605494906900_ehy870-B14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.amjcard.2014.05.038","article-title":"Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation","volume":"114","author":"Aryal","year":"2014","journal-title":"Am J Cardiol"},{"key":"2022102605494906900_ehy870-B15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/europace\/euu007","article-title":"Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation","volume":"16","author":"Providencia","year":"2014","journal-title":"Europace"},{"key":"2022102605494906900_ehy870-B16","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2013.11.039","article-title":"Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a Multicenter Prospective Registry","volume":"63","author":"Lakkireddy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102605494906900_ehy870-B17","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.hrthm.2015.02.028","article-title":"Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study","volume":"12","author":"Di Biase","year":"2015","journal-title":"Heart Rhythm"},{"key":"2022102605494906900_ehy870-B18","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2013.02.025","article-title":"Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial","volume":"61","author":"Piccini","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022102605494906900_ehy870-B19","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jacep.2017.11.005","article-title":"A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial","volume":"4","author":"Reynolds","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"2022102605494906900_ehy870-B20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10840-016-0221-7","article-title":"New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin","volume":"48","author":"Zhao","year":"2017","journal-title":"J Interv Card Electrophysiol"},{"key":"2022102605494906900_ehy870-B21","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.112.105221","article-title":"Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates","volume":"126","author":"Siegal","year":"2012","journal-title":"Circulation"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/19\/1531\/46635025\/eurheartj_40_19_1531.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/19\/1531\/46635025\/eurheartj_40_19_1531.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T05:55:46Z","timestamp":1666763746000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/40\/19\/1531\/5263768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,27]]},"references-count":21,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2018,12,27]]},"published-print":{"date-parts":[[2019,5,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehy870","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5,14]]},"published":{"date-parts":[[2018,12,27]]}}}